Chronic lymphoproliferative diseases and cardiovascular risk (a literature review)

Authors

DOI:

https://doi.org/10.14739/2310-1210.2022.5.266062

Keywords:

cardiovascular events, cardiotoxicity, polychemotherapy, diagnostics, prognostic factors

Abstract

Heart dysfunction that occurred after using of anticancer drugs and monoclonal antibodies may be a limit factor in treatment of chronic lymphoproliferative diseases (CLPD). Cancer therapy-related cardiovascular toxicity include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy.

The aim of the work is to assess the impact of anticancer treatment on the occurrence of cardiovascular events in patients with CLPD according to the world scientific literature data.

It is important to detect the cardiovascular toxicity before the development of clinical manifestations of damage to the myocardium and blood vessels. The role of markers in identifying the risk group of adverse cardiovascular events remains unclear. Early diagnostics and determination of prognostic factors of cardiovascular toxicity, which develop after anticancer therapy of CLPD, are important and not solved problems.

Conclusions. The prognosis for the development of cardiovascular events after antitumor treatment of CLPD remains unfavorable. Clinical monitoring, imaging methods, determination of the biomarker levels (natriuretic peptides, troponins) for cardiotoxicity risk stratification are recommended during antitumor treatment to identify early signs and risk of cardiotoxicity. The use of the latest biomarkers and their combinations may be a way to improve the assessment of the cardiotoxicity risk in CLPD. To date, there is no sufficient evidence on the feasibility of routine determining these biomarkers, which indicates the need to plan new studies.

Author Biographies

B. B. Samura, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Internal Diseases 3

M. O. Panasenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD student of the Department of Internal Diseases 3

References

  1. Novak, V. L., Masliak, Z. V., Klymenko, S. V., Voitsitskyi, Yu. V., Bereketa, Ya. D., Prymak, S. V., & Hutor, T. H. (2017). Pokaznyky diialnosti hematolohichnoi sluzhby Ukrainy v 2016 rotsi [Performance indicators of the hematology service of Ukraine in 2016]. Lviv, 2017, 44. [in Ukrainian].
  2. Ukrainian cancer registry statistics. (2019). Rak v Ukraini, 2017-2018. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2017-2018. Occupation, death, demonstration of oncological service]. Bulletin of National Cancer Registry of Ukraine, 20. [in Ukrainian].
  3. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
  4. Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature reviews. Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65
  5. Kryachok, I. A., & Tytorenko, I. B. (2014). Kardiotoksychnist pry provedenni khimioterapevtychnoho likuvannia u patsiientiv pokhyloho viku iz nekhodzhkinskymy limfomamy [Chemotherapy-related cardiotoxicity in elderly patients with non-Hodgkin lymphoma]. Klinicheskaya onkologiya, (1), 69-73. [in Ukrainian].
  6. Tseluiko, V. Y., & Radchenko, O. V. (2018). Serdechno-sosudistye zabolevaniya u onkologicheskikh bolnykh. Liky Ukrainy, (3), 7-20. [in Russian].
  7. Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., … ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, ehac244. Advance online publication. https://doi.org/10.1093/eurheartj/ehac244
  8. Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., Oeffinger, K. C., Salamone, J., Scott, J. M., Squires, R. W., Thomas, R. J., Treat-Jacobson, D. J., Wright, J. S., & American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease (2019). Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation, 139(21), e997-e1012. https://doi.org/10.1161/CIR.0000000000000679
  9. Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs that cause or worsen heart failure. Review of American Heart Association Guidelines]. Praktychna anhiolohiia, (1), 52-56. [in Russian].
  10. Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma relapse involving the heart and presenting as acute cardiac failure. Journal of clinical oncology, 32(18), e67-e68. https://doi.org/10.1200/JCO.2012.47.6713
  11. Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., McMillan, A., Brownell, A., Kruger, A., Lister, A., Hoskin, P., O'Doherty, M., & Barrington, S. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. The New England journal of medicine, 372(17), 1598-1607. https://doi.org/10.1056/NEJMoa1408648
  12. Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P., Krol, A. D., van der Maazen, R. W., Roesink, J., Raemaekers, J. M., de Boer, J. P., Zijlstra, J. M., van Imhoff, G. W., Petersen, E. J., Poortmans, P. M., Beijert, M., Lybeert, M. L., Mulder, I., Visser, O., Louwman, M. W., Krul, I. M., Lugtenburg, P. J., … van Leeuwen, F. E. (2015). Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. The New England journal of medicine, 373(26), 2499-2511. https://doi.org/10.1056/NEJMoa1505949
  13. De Luca, V., Gallio, E., Bartoncini, S., Giglioli, F. R., Sardo, A., Cavallin, C., Iorio, G. C., Orlandi, E., Parise, R., Palladino, C., Buonavita, A., Fiandra, C., Levis, M., & Ricardi, U. (2021). Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients. Practical radiation oncology, 11(1), 66-73. https://doi.org/10.1016/j.prro.2020.06.005
  14. Gevaert, S. A., Halvorsen, S., Sinnaeve, P. R., Sambola, A., Gulati, G., Lancellotti, P., Van Der Meer, P., Lyon, A. R., Farmakis, D., Lee, G., Boriani, G., Wechalekar, A., Okines, A., & Asteggiano, R. (2021). Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. European heart journal. Acute cardiovascular care, 10(8), 947-959. https://doi.org/10.1093/ehjacc/zuab056
  15. van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., Kok, W. E., Aleman, B. M., & van Leeuwen, F. E. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA internal medicine, 175(6), 1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180
  16. van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., Aleman, B. M., & van Leeuwen, F. E. (2016). Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of clinical oncology, 34(3), 235-243. https://doi.org/10.1200/JCO.2015.63.4444
  17. Akazawa H. (2017). [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach]. Cancer & chemotherapy, 44(13), 2058-2063.
  18. Rokyta, O. I., & Rudenko, Yu. V. (2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist. Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Chastyna I [Treatment of oncological diseases and cardiovascular toxicity. Viewpoint of the European Society of Cardiology. Part 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].
  19. Bahia, L., de Aguiar, L. G., Villela, N. R., Bottino, D., & Bouskela, E. (2006). O endotélio na síndrome metabólica [The endothelium in the metabolic syndrome]. Arquivos brasileiros de endocrinologia e metabologia, 50(2), 291-303. https://doi.org/10.1590/s0004-27302006000200015
  20. Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European heart journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181
  21. Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, (5-6), 47-52. [in Ukrainian].
  22. Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., Morarji, K., Brown, T. D., Ismail, N. A., Dweck, M. R., Di Pietro, E., Roughton, M., Wage, R., Daryani, Y., O'Hanlon, R., Sheppard, M. N., Alpendurada, F., Lyon, A. R., Cook, S. A., Cowie, M. R., … Prasad, S. K. (2013). Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363
  23. Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation, 126(23), 2749-2763. https://doi.org/10.1161/CIRCULATIONAHA.112.100560
  24. Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European heart journal. Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
  25. Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 37(36), 2768-2801. https://doi.org/10.1093/eurheartj/ehw211
  26. Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., Neilan, T. G., … Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European journal of heart failure, 22(11), 1945-1960. https://doi.org/10.1002/ejhf.1920
  27. Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131(22), 1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
  28. Wang, L., Tan, T. C., Halpern, E. F., Neilan, T. G., Francis, S. A., Picard, M. H., Fei, H., Hochberg, E. P., Abramson, J. S., Weyman, A. E., Kuter, I., & Scherrer-Crosbie, M. (2015). Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. The American journal of cardiology, 116(3), 442-446. https://doi.org/10.1016/j.amjcard.2015.04.064
  29. Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J., Shankar, S., Sieswerda, E., Skinner, R., Steinberger, J., van Dalen, E. C., van der Pal, H., Wallace, W. H., Levitt, G., Kremer, L. C., & International Late Effects of Childhood Cancer Guideline Harmonization Group (2015). Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet. Oncology, 16(3), e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7
  30. Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., Zamorano, J. L., Aboyans, V., Achenbach, S., Agewall, S., … Document Reviewers (2017). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European journal of heart failure, 19(1), 9-42. https://doi.org/10.1002/ejhf.654
  31. Askolskyi, A. V., Sivak, L. A., Zharinov, O. I., Antomonov, M. Y., & Shevchuk, L. A. (2017). Profilaktyka rannoi antratsyklin-indukovanoi kardiotoksychnosti polikhimioterapii u khvorykh na rak hrudnoi zalozy [Prevention of early anthracycline-induced cardiotoxicity in patients with breast cancer]. Klinicheskaya onkologiya, (1), 45-50. [in Ukrainian].
  32. Drafts, B. C., Twomley, K. M., D'Agostino, R., Jr, Lawrence, J., Avis, N., Ellis, L. R., Thohan, V., Jordan, J., Melin, S. A., Torti, F. M., Little, W. C., Hamilton, C. A., & Hundley, W. G. (2013). Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC. Cardiovascular imaging, 6(8), 877-885. https://doi.org/10.1016/j.jcmg.2012.11.017
  33. Gribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018). Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British journal of haematology, 180(5), 666-679. https://doi.org/10.1111/bjh.15080
  34. Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., Woyach, J. A., Awan, F., & Addison, D. (2019). Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 134(22), 1919-1928. https://doi.org/10.1182/blood.2019000840
  35. Salem, J. E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., Roden, D. M., & Moslehi, J. J. (2019). Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology, 74(13), 1667-1678. https://doi.org/10.1016/j.jacc.2019.07.056
  36. Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., Garcia-Marco, J. A., Mato, A., Pinilla-Ibarz, J., Seymour, J. F., Lepretre, S., Stilgenbauer, S., Robak, T., Rothbaum, W., Izumi, R., Hamdy, A., … Jurczak, W. (2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology, 39(31), 3441-3452. https://doi.org/10.1200/JCO.21.01210
  37. Brown, J. R., Byrd, J. C., Ghia, P., Sharman, J. P., Hillmen, P., Stephens, D. M., Sun, C., Jurczak, W., Pagel, J. M., Ferrajoli, A., Patel, P., Tao, L., Kuptsova-Clarkson, N., Moslehi, J., & Furman, R. R. (2022). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107(6), 1335-1346. https://doi.org/10.3324/haematol.2021.278901
  38. Svennberg, E., Tjong, F., Goette, A., Akoum, N., Di Biase, L., Bordachar, P., Boriani, G., Burri, H., Conte, G., Deharo, J. C., Deneke, T., Drossart, I., Duncker, D., Han, J. K., Heidbuchel, H., Jais, P., de Oliviera Figueiredo, M. J., Linz, D., Lip, G., Malaczynska-Rajpold, K., … Sinner, M. (2022). How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace, 24(6), 979-1005. https://doi.org/10.1093/europace/euac038
  39. Abdel-Qadir, H., Sabrie, N., Leong, D., Pang, A., Austin, P. C., Prica, A., Nanthakumar, K., Calvillo-Argüelles, O., Lee, D. S., & Thavendiranathan, P. (2021). Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of clinical oncology, 39(31), 3453-3462. https://doi.org/10.1200/JCO.21.00693
  40. Waxman, A. J., Clasen, S., Hwang, W. T., Garfall, A., Vogl, D. T., Carver, J., O'Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., & Weiss, B. M. (2018). Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA oncology, 4(3), e174519. https://doi.org/10.1001/jamaoncol.2017.4519
  41. Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., & Lonial, S. (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 98(11), 1753-1761. https://doi.org/10.3324/haematol.2013.089334
  42. Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., Goodman, S. A., Harrell, S. L., Kassim, A. A., Jadhav, T., Jagasia, M., Moslehi, J., O'Quinn, R., Savona, M. R., Slosky, D., Smith, A., … Lenihan, D. (2019). Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of clinical oncology, 37(22), 1946-1955. https://doi.org/10.1200/JCO.19.00231
  43. Fakhri, B., Fiala, M. A., Shah, N., Vij, R., & Wildes, T. M. (2020). Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer, 126(4), 808-813. https://doi.org/10.1002/cncr.32601
  44. Mancuso, S., Carlisi, M., Sarocchi, M., Napolitano, M., & Siragusa, S. (2018). Cardio-oncology in multiple myeloma: is it time for a specific focus?. Leukemia & lymphoma, 59(7), 1764-1766. https://doi.org/10.1080/10428194.2017.1393674
  45. Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. (2016). 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. European journal of haematology, 97(1), 25-32. https://doi.org/10.1111/ejh.12677
  46. Gavazzoni, M., Lombardi, C. M., Vizzardi, E., Gorga, E., Sciatti, E., Rossi, L., Belotti, A., Rossi, G., Metra, M., & Raddino, R. (2018). Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European journal of pharmacology, 838, 85-90. https://doi.org/10.1016/j.ejphar.2018.09.014
  47. Fradley, M. G., Groarke, J. D., Laubach, J., Alsina, M., Lenihan, D. J., Cornell, R. F., Maglio, M., Shain, K. H., Richardson, P. G., & Moslehi, J. (2018). Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British journal of haematology, 180(2), 271-275. https://doi.org/10.1111/bjh.14970
  48. Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., … ASPIRE Investigators (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321
  49. Willis, M. S., & Patterson, C. (2013). Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?. The New England journal of medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180
  50. Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Effets indésirables cardiaques des chimiothérapies [Cardiotoxicity of chemotherapies]. Presse medicale, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014
  51. Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic noncommunicable diseases: emphasis on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, 2, 26-32. [in Ukrainian].
  52. Lancellotti, P., Suter, T. M., López-Fernández, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J. L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation. European heart journal, 40(22), 1756-1763. https://doi.org/10.1093/eurheartj/ehy453
  53. Jaworski, C., Mariani, J. A., Wheeler, G., & Kaye, D. M. (2013). Cardiac complications of thoracic irradiation. Journal of the American College of Cardiology, 61(23), 2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090
  54. Vydyborets, S. V., Hartovska, I. R., Borysenko, Ye. O., & Maiko, O. V. Markery endohennoi intoksykatsii ta infuziino-transfuziina terapiia khvorykh na hostri leikozy v protsesi intensyvnoi khimioterapii [Markers of endogenous intoxication and infusion-transfusion therapy of patients with hostile leukemia during intensive chemotherapy]. Semeinaya meditsina, (6), 111-114. [in Ukrainian].
  55. Visseren, F., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J. M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., Di Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F., Hollander, M., Jankowska, E. A., … ESC Scientific Document Group (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European heart journal, 42(34), 3227-3337. https://doi.org/10.1093/eurheartj/ehab484
  56. Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H. J., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of clinical oncology, 33(5), 394-402. https://doi.org/10.1200/JCO.2014.56.1373
  57. Szmit, S., Jurczak, W., Zaucha, J. M., Drozd-Sokołowska, J., Spychałowicz, W., Joks, M., Długosz-Danecka, M., & Torbicki, A. (2014). Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. Journal of the American Society of Hypertension : JASH, 8(11), 791-799. https://doi.org/10.1016/j.jash.2014.08.009
  58. Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., Mertens, A. C., Border, W., Durand, J. B., Robison, L. L., & Meacham, L. R. (2013). Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. Journal of clinical oncology, 31(29), 3673-3680. https://doi.org/10.1200/JCO.2013.49.3205
  59. Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R., Edvardsen, T., Gaemperli, O., Galderisi, M., Griffin, B., Heidenreich, P. A., Nieman, K., Plana, J. C., Port, S. C., Scherrer-Crosbie, M., Schwartz, R. G., Sebag, I. A., … Society of Cardiovascular Computed Tomography (2013). Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European heart journal. Cardiovascular Imaging, 14(8), 721-740. https://doi.org/10.1093/ehjci/jet123
  60. Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M. H., Rietzschel, E. R., Rudski, L., Spencer, K. T., Tsang, W., & Voigt, J. U. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 28(1), 1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
  61. Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., … ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of oncology, 31(2), 171-190. https://doi.org/10.1016/j.annonc.2019.10.023
  62. Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., Barberis, V., Flachskampf, F. A., Čeponienė, I., Haegler-Laube, E., Suter, T., Lapinskas, T., Prasad, S., de Boer, R. A., Wechalekar, K., Anker, M. S., … Lyon, A. R. (2020). Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European journal of heart failure, 22(9), 1504-1524. https://doi.org/10.1002/ejhf.1957
  63. Hoffmann, R., Barletta, G., von Bardeleben, S., Vanoverschelde, J. L., Kasprzak, J., Greis, C., & Becher, H. (2014). Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. Journal of the American Society of Echocardiography, 27(3), 292-301. https://doi.org/10.1016/j.echo.2013.12.005
  64. van Kalsbeek, R. J., Mulder, R. L., Skinner, R., & Kremer, L. (2021). The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Frontiers of hormone research, 54, 1-15. https://doi.org/10.1159/000514693
  65. Thavendiranathan, P., Negishi, T., Coté, M. A., Penicka, M., Massey, R., Cho, G. Y., Hristova, K., Vinereanu, D., Popescu, B. A., Izumo, M., Negishi, K., Marwick, T. H., & SUCCOUR Investigators (2018). Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy. JACC. Cardiovascular imaging, 11(8), 1109-1118. https://doi.org/10.1016/j.jcmg.2018.03.003
  66. Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA cardiology, 4(10), 1007-1018. https://doi.org/10.1001/jamacardio.2019.2952
  67. Cheng, S., Larson, M. G., McCabe, E. L., Osypiuk, E., Lehman, B. T., Stanchev, P., Aragam, J., Benjamin, E. J., Solomon, S. D., & Vasan, R. S. (2013). Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study. Journal of the American Society of Echocardiography, 26(11), 1258-1266.e2. https://doi.org/10.1016/j.echo.2013.07.002
  68. Thavendiranathan, P., Poulin, F., Lim, K. D., Plana, J. C., Woo, A., & Marwick, T. H. (2014). Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology, 63(25 Pt A), 2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073
  69. Tsai, H. R., Gjesdal, O., Wethal, T., Haugaa, K. H., Fosså, A., Fosså, S. D., & Edvardsen, T. (2011). Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. The American journal of cardiology, 107(3), 472-477. https://doi.org/10.1016/j.amjcard.2010.09.048
  70. Mawad, W., & Friedberg, M. K. (2017). The continuing challenge of evaluating diastolic function by echocardiography in children: developing concepts and newer modalities. Current opinion in cardiology, 32(1), 93-100. https://doi.org/10.1097/HCO.0000000000000346
  71. Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., Pedri, S., Ito, Y., Abe, Y., Metz, S., Song, J. H., Hamilton, J., Sengupta, P. P., Kolias, T. J., d'Hooge, J., Aurigemma, G. P., Thomas, J. D., & Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European heart journal. Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184
  72. Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., Nohria, A., … Valent, P. (2022). Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European heart journal, 43(4), 280-299. https://doi.org/10.1093/eurheartj/ehab674
  73. Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013). Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035
  74. Houbois, C. P., Nolan, M., Somerset, E., Shalmon, T., Esmaeilzadeh, M., Lamacie, M. M., Amir, E., Brezden-Masley, C., Koch, C. A., Thevakumaran, Y., Yan, A. T., Marwick, T. H., Wintersperger, B. J., & Thavendiranathan, P. (2021). Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC. Cardiovascular imaging, 14(5), 962-974. https://doi.org/10.1016/j.jcmg.2020.09.039
  75. Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J. B., Joshi, V., Hudson, M. M., Robison, L. L., & Flamm, S. D. (2012). Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. Journal of clinical oncology, 30(23), 2876-2884. https://doi.org/10.1200/JCO.2011.40.3584
  76. Phillips, W. J., Johnson, C., Law, A., Turek, M., Small, A. R., Dent, S., Ruddy, T. D., Beanlands, R. S., Chow, B., & Small, G. R. (2019). Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. International journal of cardiology, 289, 138-143. https://doi.org/10.1016/j.ijcard.2019.01.056
  77. Porta-Sánchez, A., Gilbert, C., Spears, D., Amir, E., Chan, J., Nanthakumar, K., & Thavendiranathan, P. (2017). Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association, 6(12), e007724. https://doi.org/10.1161/JAHA.117.007724
  78. Praga, C., Beretta, G., Vigo, P. L., Lenaz, G. R., Pollini, C., Bonadonna, G., Canetta, R., Castellani, R., Villa, E., Gallagher, C. G., von Melchner, H., Hayat, M., Ribaud, P., De Wasch, G., Mattsson, W., Heinz, R., Waldner, R., Kolaric, K., Buehner, R., Ten Bokkel-Huyninck, W., … Mayr, A. C. (1979). Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer treatment reports, 63(5), 827-834.
  79. Salem, J. E., Nguyen, L. S., Moslehi, J. J., Ederhy, S., Lebrun-Vignes, B., Roden, D. M., Funck-Brentano, C., & Gougis, P. (2021). Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European heart journal, 42(38), 3915-3928. https://doi.org/10.1093/eurheartj/ehab362
  80. Lentz, R., Feinglass, J., Ma, S., & Akhter, N. (2019). Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leukemia & lymphoma, 60(6), 1447-1453. https://doi.org/10.1080/10428194.2018.1533129
  81. Singla, A., Hogan, W. J., Ansell, S. M., Buadi, F. K., Dingli, D., Dispenzieri, A., Gastineau, D. A., Gertz, M. A., Hayman, S. R., Inwards, D. J., Johnston, P. B., Lacy, M. Q., Litzow, M. R., Micallef, I. N., Porrata, L. F., & Kumar, S. K. (2013). Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of blood and marrow transplantation, 19(8), 1233-1237. https://doi.org/10.1016/j.bbmt.2013.05.019
  82. Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prognosis and evaluation of the effectiveness of therapy for heart failure with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].
  83. Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., Von Haehling, S., Belenkov, Y., … Lyon, A. R. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European journal of heart failure, 22(11), 1966-1983. https://doi.org/10.1002/ejhf.2017
  84. Michel, L., Mincu, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., & Totzeck, M. (2020). Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. European journal of heart failure, 22(2), 350-361. https://doi.org/10.1002/ejhf.1631
  85. Xue, K., Gu, J. J., Zhang, Q., Liu, X., Wang, J., Li, X. Q., Luo, J., Hernandez-Ilizaliturri, F. J., Fernandez, S. F., Czuczman, M. S., Cao, J., Hong, X., & Guo, Y. (2016). Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget, 7(22), 32519-32531. https://doi.org/10.18632/oncotarget.8685
  86. Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J., Kozhuharov, N., Coats, A., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P. M., Meijers, W. C., Bayes-Genis, A., Mueller, T., Richards, M., Januzzi, J. L., Jr, & Heart Failure Association of the European Society of Cardiology (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European journal of heart failure, 21(6), 715-731. https://doi.org/10.1002/ejhf.1494
  87. Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., Köstler, W., Zöchbauer-Müller, S., Marosi, C., Kornek, G., Auerbach, L., Schneider, S., Parschalk, B., Scheithauer, W., Pirker, R., Drach, J., … Pacher, R. (2015). Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart (British Cardiac Society), 101(23), 1874-1880. https://doi.org/10.1136/heartjnl-2015-307848
  88. López-Sendón, J., Álvarez-Ortega, C., Zamora Auñon, P., Buño Soto, A., Lyon, A. R., Farmakis, D., Cardinale, D., Canales Albendea, M., Feliu Batlle, J., Rodríguez Rodríguez, I., Rodríguez Fraga, O., Albaladejo, A., Mediavilla, G., González-Juanatey, J. R., Martínez Monzonis, A., Gómez Prieto, P., González-Costello, J., Serrano Antolín, J. M., Cadenas Chamorro, R., & López Fernández, T. (2020). Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European heart journal, 41(18), 1720-1729. https://doi.org/10.1093/eurheartj/ehaa006
  89. Beer, L. A., Kossenkov, A. V., Liu, Q., Luning Prak, E., Domchek, S., Speicher, D. W., & Ky, B. (2016). Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation research, 119(10), 1135-1144. https://doi.org/10.1161/CIRCRESAHA.116.309004
  90. Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095
  91. Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of clinical oncology, 30(10), 1042-1049. https://doi.org/10.1200/JCO.2010.30.3404
  92. Loar, R. W., Noel, C. V., Tunuguntla, H., Colquitt, J. L., & Pignatelli, R. H. (2018). State of the art review: Chemotherapy-induced cardiotoxicity in children. Congenital heart disease, 13(1), 5-15. https://doi.org/10.1111/chd.12564
  93. Vianello, E., Dozio, E., Tacchini, L., Frati, L., & Corsi Romanelli, M. M. (2019). ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology, 116, 105619. https://doi.org/10.1016/j.biocel.2019.105619
  94. Aula, H., Skyttä, T., Tuohinen, S., Luukkaala, T., Hämäläinen, M., Virtanen, V., Raatikainen, P., Moilanen, E., & Kellokumpu-Lehtinen, P. L. (2020). ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast (Edinburgh, Scotland), 49, 183-186. https://doi.org/10.1016/j.breast.2019.12.001
  95. Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4
  96. Huang, G., Zhai, J., Huang, X., & Zheng, D. (2018). Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine, 97(38), e12447. https://doi.org/10.1097/MD.0000000000012447
  97. Samura, B., & Panasenko, M. (2022). SST2 AS a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian medical news, (326), 18-22.
  98. Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International journal of molecular sciences, 19(12), 3701. https://doi.org/10.3390/ijms19123701
  99. FDA. (n.d.). 510(k) Substantial equivalence determination decision summary (No K093758). http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf
  100. Syvolap, V. D., & Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fibrosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, (5), 13-17. [in Ukrainain].
  101. Lok, D. J., Lok, S. I., Bruggink-André de la Porte, P. W., Badings, E., Lipsic, E., van Wijngaarden, J., de Boer, R. A., van Veldhuisen, D. J., & van der Meer, P. (2013). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical research in cardiology, 102(2), 103-110. https://doi.org/10.1007/s00392-012-0500-y
  102. Meijers, W. C., Januzzi, J. L., deFilippi, C., Adourian, A. S., Shah, S. J., van Veldhuisen, D. J., & de Boer, R. A. (2014). Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. American heart journal, 167(6), 853-60.e4. https://doi.org/10.1016/j.ahj.2014.02.011
  103. van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., Muntendam, P., van Veldhuisen, D. J., & de Boer, R. A. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circulation. Heart failure, 6(2), 219-226. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000129
  104. Chen, A., Hou, W., Zhang, Y., Chen, Y., & He, B. (2015). Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. International journal of cardiology, 182, 168-170. https://doi.org/10.1016/j.ijcard.2014.12.137
  105. Weir, R. A., Petrie, C. J., Murphy, C. A., Clements, S., Steedman, T., Miller, A. M., McInnes, I. B., Squire, I. B., Ng, L. L., Dargie, H. J., & McMurray, J. J. (2013). Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation. Heart failure, 6(3), 492-498. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000146
  106. Thijssen, V. L., Heusschen, R., Caers, J., & Griffioen, A. W. (2015). Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica et biophysica acta, 1855(2), 235-247. https://doi.org/10.1016/j.bbcan.2015.03.003
  107. Felker, G. M., Fiuzat, M., Shaw, L. K., Clare, R., Whellan, D. J., Bettari, L., Shirolkar, S. C., Donahue, M., Kitzman, D. W., Zannad, F., Piña, I. L., & O'Connor, C. M. (2012). Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circulation. Heart failure, 5(1), 72-78. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963637

Downloads

Published

2022-11-09

How to Cite

1.
Samura BB, Panasenko MO. Chronic lymphoproliferative diseases and cardiovascular risk (a literature review). Zaporozhye Medical Journal [Internet]. 2022Nov.9 [cited 2026May14];24(5):613-24. Available from: https://zmj.zsmu.edu.ua/article/view/266062

Issue

Vol. 24 No. 5 (2022)

Section

Review

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons